2.1  Participants
Twenty-four adolescents (age range = 12–15 years) diagnosed with ASD (20 males, 14.03 ± 1.20 years, 23 right-handed, 7 medicated, IQ = 90.79 ± 23.76) and 24 healthy controls (19 males, 14.27 ± 1.12 years, 23 right-handed, IQ = 110.04 ± 12.21) were recruited. Participants in the clinical group had a diagnosis of ASD, informed by the Autism Diagnostic Observation Schedule-Generic (ADOS-G; Lord et al., 2000), or Autism Diagnostic Observation Schedule-2 (ADOS-2; Rutter et al., 2012), and confirmed by expert clinical judgment. Exclusion criteria for both groups included a history of neurological or neurodevelopment disorders (other than ASD for participants in the clinical group), acquired brain injury, uncorrected vision, colour blindness, IQ ≤ 65 and standard contraindications to MEG and MRI. Use of psychotropic medications was an exclusion criterion for control participants only, due to difficulty in recruiting medication-naïve adolescents with ASD. Seven participants with ASD were on medication, which included Bicentin, Celexa, Cipralex, Concerta, Gabapentin, Ritalin, Seroquel, Strattera and Zeldox. The study was approved by The Hospital for Sick Children Research Ethics Board and written informed consent was obtained from all participants and their legal guardians.